Table of Content PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pipeline portfolio PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by type of disease • Global hemophilia A drugs market • Global hemophilia inhibitors treatment market • Global hemophilia B drugs market • Global von Willebrand disease treatment market PART 08: Market segmentation by type of therapy • Recombinant therapies • Plasma-derived therapies PART 09: Market segmentation by type of disease management • Prophylaxis • On-demand therapy • Inhibitor therapy PART 10: Geographical segmentation • Hemophilia drugs market in Americas • Hemophilia drugs market in EMEA • Hemophilia drugs market in APAC PART 11: Market drivers • Focus on prophylactic treatment • Drugs with prolonged action • Improved diagnostic procedures PART 12: Impact of drivers PART 13: Market challenges • Low diagnosis rate • High entry barriers • Cost-intensive complex treatment PART 14: Impact of drivers and challenges PART 15: Market trends • Increase in technological innovations • Development of gene therapy products • Centralized buyers should pave the way to increased penetration PART 16: Vendor landscape • Competitive scenario • Other prominent vendors PART 17: Key vendor analysis • Baxalta • Bayer • CSL Behring • Novo Nordisk • Pfizer PART 18: Appendix • List of abbreviations PART 19: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Process of gene therapy Exhibit 03: Key buying criteria for global hemophilia drugs market 2015 Exhibit 04: Key customer segments of hemophilia drugs market Exhibit 05: Pipeline portfolio: Global hemophilia drugs market Exhibit 06: Pipeline share of major companies Exhibit 07: Global hemophilia drugs market snapshot: Developed and emerging markets 2015 Exhibit 08: Global hemophilia drugs market 2015-2020 ($ billions) Exhibit 09: Impact of factors affecting the market 2015 and 2020 Exhibit 10: Five forces analysis Exhibit 11: Segmentation of global hemophilia drugs market by disease type based on revenue 2015 Exhibit 12: Global hemophilia drugs market segmentation growth lifecycle analysis Exhibit 13: Global hemophilia drugs market by disease type 2015-2020 Exhibit 14: Global hemophilia A drugs market 2015-2020 ($ billions) Exhibit 15: Global hemophilia inhibitors treatment market 2015-2020 ($ billions) Exhibit 16: Global hemophilia B drugs market 2015-2020 ($ billions) Exhibit 17: Global von Willebrand disease treatment market 2015-2020 ($ millions) Exhibit 18: Segmentation of global hemophilia drugs market by type of therapy based on revenue 2015 Exhibit 19: Global hemophilia drugs market by type of therapy 2015-2020 Exhibit 20: Recombinant therapies in global hemophilia drugs market 2015-2020 ($ billions) Exhibit 21: Plasma-derived therapies in global hemophilia drugs market 2015-2020 ($ billions) Exhibit 22: Segmentation of hemophilia inhibitors treatment market by type of disease management based on revenue 2015 Exhibit 23: Global hemophilia drugs market by geography 2015-2020 Exhibit 24: Percentage share of global hemophilia drugs market by geography 2015 and 2020 Exhibit 25: Global hemophilia drugs market segmentation by geography 2015-2020 ($ billions) Exhibit 26: Global share of hemophilia drugs market by geography 2015 Exhibit 27: Global hemophilia drugs market segmentation by region: Market growth lifecycle analysis 2015 Exhibit 28: Global hemophilia drugs market: Country analysis based on revenue and growth rate Exhibit 29: Opportunity analysis of hemophilia drugs market in Americas Exhibit 30: Hemophilia drugs market in Americas 2015-2020 ($ billions) Exhibit 31: Opportunity analysis of hemophilia drugs market in EMEA Exhibit 32: Hemophilia drugs market in EMEA 2015-2020 ($ billions) Exhibit 33: Opportunity analysis of hemophilia drugs market in APAC Exhibit 34: Hemophilia drugs market in APAC 2015-2020 ($ billions) Exhibit 35: Impact of drivers Exhibit 36: Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016 Exhibit 37: Impact of drivers and challenges Exhibit 38: Gene therapies under development for hemophilia Exhibit 39: Market share of vendors 2015 Exhibit 40: Geographical presence of key vendors Exhibit 41: Competitive scenario of global hemophilia drugs market vendors 2015-2020 Exhibit 42: Baxalta: Strength assessment Exhibit 43: Baxalta: Strategy assessment Exhibit 44: Baxalta: Opportunity assessment Exhibit 45: Baxalta: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions) Exhibit 46: Bayer: Strength assessment Exhibit 47: Bayer: Strategy assessment Exhibit 48: Bayer: Opportunity assessment Exhibit 49: Bayer: YoY revenue and growth rate of Kogenate FS 2013-2015 ($ billions) Exhibit 50: CSL Behring: Strength assessment Exhibit 51: CSL Behring strategy assessment Exhibit 52: CSL Behring opportunity assessment Exhibit 53: CSL Behring: YoY revenue and growth rate of hemophilia drugs 2013-2015 ($ billions) Exhibit 54: Novo Nordisk: Strength assessment Exhibit 55: Novo Nordisk: Strategy assessment Exhibit 56: Novo Nordisk: Opportunity assessment Exhibit 57: Novo Nordisk: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions) Exhibit 58: Pfizer: Strength assessment Exhibit 59: Pfizer: Strategy assessment Exhibit 60: Pfizer: Opportunity assessment Exhibit 61: Pfizer: Revenue of ReFacto AF/XYNTHA and BeneFIX 2015 ($ millions)

Baxalta, Bayer, CSL Behring, Novo Nordisk, Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, UniQure Biopharma.